Novo Nordisk (NVO), maker of popular weight-loss drugs 澳洲幸运5官方开奖结果体彩网:Ozempic and Wegovy, is set to report third-quarter earnings Wednesday morning, with Wall Street analysts generally bullish on the Danish drugmaker's stock.

Analysts with current ratings tracked by Visible Alpha have six "buy" and five "hold" or 澳洲幸运5官方开奖结果体彩网:equivalent ratings. The average 澳洲幸运5官方开奖结果体彩网:price target for the company's shares on its home stock exchange is 963.36 澳洲幸运5官方开奖结果体彩网:Danish krone (about $140), about 28% over its Monday close.

The company could face increased competition in the weight-loss market in coming years. Companies 澳洲幸运5官方开奖结果体彩网:like Viking Therapeutics (VKTX) and AstraZeneca () this week offered new data for their own weight-loss drugs in various stages of clinical trials.

Novo Nordisk, Eli Lilly Have Production 'Moats' Over Competitors

Deutsche Bank analysts said Monday that they believe Novo Nordisk, along with Mounjaro and Zepbound-maker Eli Lilly (LLY), have "澳洲幸运5官方开奖结果体彩网:built moats" that will make it difficult for other companies to scale production enough to challenge their dominant positions in the weight-loss market.

Analysts expect Novo Nordisk to report 72.17 billion krone ($10.48 billion) in revenue for the quarter, with Ozempic and Wegovy sales projected to rise 28% and 63%, respectively, from the same tim꧋e last year.

Eli Lilly's results 澳洲幸运5官方开奖结果体彩网:missed estimates last week, with sales of Mounjaro and Zepbou💦nd continuing to rise and bolster Lilly's revenuꦦe.